

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)



(10) International Publication Number
WO 2021/188034 A1

(51) International Patent Classification:

C12N 15/79 (2006.01) C12N 15/67 (2006.01)
C12N 15/63 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/SE2021/050233

(22) International Filing Date:

17 March 2021 (17.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2030080-2	17 March 2020 (17.03.2020)	SE
2030082-8	17 March 2020 (17.03.2020)	SE
2030083-6	17 March 2020 (17.03.2020)	SE
2030084-4	17 March 2020 (17.03.2020)	SE
2030085-1	17 March 2020 (17.03.2020)	SE
2030086-9	17 March 2020 (17.03.2020)	SE

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **XBRANE BIOPHARMA AB** [SE/SE]; Reutzius väg 8, 171 65 Solna (SE).

(72) Inventors: **MIRZADEH, Kiavash**; Storgatan 70C, 17152 SOLNA (SE). **RAMBERG, Veronica**; Bokvägen 7C, 178 51 Ekerö (SE). **CHATZISSAVIDOU, Nathalie**; Dalgatan 7, 151 33 Södertälje (SE). **SAMUELSON, Patrik**; Älgövägen 21, 133 36 Saltsjöbaden (SE). **BASHIRI, Siavash**; Tegnérgatan 18, 11358 Stockholm (SE). **EDEBRINK, Per**; Snoilskyvägen 8, 112 54 Stockholm (SE). **STEVENSON, Joanne**; Amerikgatan 46, 151 34 Södertälje (SE). **VIKSTRÖM, David**; Vallmovägen 2, 194 68 Upplands Väsby (SE).

(74) Agent: **YILDIRIM, Håkan**; Xbrane Biopharma AB, Patent Department, Reutzius väg 8, 171 65 Solna (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: NOVEL COMBINATION OF TIS SEQUENCE AND SIGNAL PEPTIDE SEQUENCE FOR EXPRESSING A RECOMBINANT PROTEIN

(57) Abstract: The present invention relates to DNA constructs comprising a novel TIS sequence. The TIS sequence transcribes into an RNA motif that functions as the protein translation initiation site in an mRNA transcript. The DNA construct may further comprise a nucleic acid sequence encoding signal peptide. Additionally, the DNA constructs may also comprise a nucleic acid sequence encoding a recombinant protein or one or more polypeptide chains thereof. The invention further relates to an expression vector, expression cassette and host cell which comprise said DNA constructs. Furthermore, the present invention relates to a recombinant protein expressed by the host cell as well as a method for expressing the recombinant protein.



WO 2021/188034 A1